Enlivex Therapeutics (ENLV) News Today $1.27 +0.04 (+3.25%) (As of 09/6/2024 ET) Add Compare Share Share HeadlinesStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 November 2021 October 2021 Time Period September 2, 2024 | uk.finance.yahoo.comEnlivex Therapeutics Ltd. (ENLV.TA)August 29, 2024 | americanbankingnews.comEnlivex Therapeutics (NASDAQ:ENLV) Rating Increased to Strong-Buy at EF Hutton Acquisition Co. IAugust 21, 2024 | finance.yahoo.comValneva SE (AYJ0.BE)July 23, 2024 | markets.businessinsider.comEnlivex Receives Regulatory Authorization For The Initiation Of A Phase I Clinical Trial To Evaluate Allocetra In Patients With Psoriatic ArthritisJuly 19, 2024 | finanznachrichten.deEnlivex Therapeutics and Biotricity Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVJune 17, 2024 | globenewswire.comEnlivex Announces Positive Interim Data Readout from a Phase I/II Trial Evaluating Allocetra in End-Stage Knee OsteoarthritisMay 29, 2024 | globenewswire.comEnlivex Therapeutics Closes up to $15 Million Registered Direct OfferingMay 28, 2024 | globenewswire.comEnlivex Therapeutics Announces up to $15 Million Registered Direct OfferingMay 21, 2024 | finance.yahoo.comWe're Keeping An Eye On Enlivex Therapeutics' (NASDAQ:ENLV) Cash Burn RateApril 29, 2024 | finance.yahoo.comEnlivex CEO Issues Letter to Shareholders – Perspectives on Recent EventsApril 22, 2024 | finance.yahoo.comEnlivex Announces Dosing of First Two Patients in its Randomized, Controlled Phase I/II Trial Evaluating Allocetra™ in Patients with Knee OsteoarthritisApril 18, 2024 | msn.comYet Another Biotech Stock Has Found Success During Tuesday's SessionApril 17, 2024 | msn.comEnlivex Therapeutics (ENLV) Price Target Decreased by 41.67% to 7.14April 16, 2024 | finance.yahoo.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company’s Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 16, 2024 | globenewswire.comEnlivex Announces Authorization from the Danish Regulatory Agency for the Company's Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Patients with Knee OsteoarthritisApril 13, 2024 | stockhouse.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra(TM) In Patients With SepsisApril 12, 2024 | marketbeat.comEnlivex Therapeutics (NASDAQ:ENLV) Price Target Cut to $7.00 by Analysts at HC WainwrightHC Wainwright dropped their price objective on shares of Enlivex Therapeutics from $12.00 to $7.00 and set a "buy" rating on the stock in a research note on Friday.April 11, 2024 | finance.yahoo.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | globenewswire.comEnlivex to Host Webcast on April 12, 2024 at 8:30 a.m. Eastern Time to Discuss Topline Results from Its Phase II Trial Evaluating Allocetra™ In Patients with SepsisApril 11, 2024 | msn.comNasdaq Gains Over 50 Points; US Producer Prices Increase In MarchApril 11, 2024 | msn.comDow Dips 100 Points; CarMax Earnings Miss ViewsApril 11, 2024 | msn.comEnlivex stock plunges 50% on mixed results from sepsis studyApril 11, 2024 | globenewswire.comEnlivex Announces Topline Results of Its Phase II Trial Evaluating Allocetra™ In Patients With SepsisApril 5, 2024 | msn.comENLV Stock Earnings: Enlivex Therapeutics Misses EPS for Q4 2023April 2, 2024 | marketbeat.comEnlivex Therapeutics Ltd. (NASDAQ:ENLV) Short Interest Up 15.4% in MarchEnlivex Therapeutics Ltd. (NASDAQ:ENLV - Get Free Report) saw a significant increase in short interest in the month of March. As of March 15th, there was short interest totalling 261,500 shares, an increase of 15.4% from the February 29th total of 226,600 shares. Based on an average trading volume of 108,300 shares, the days-to-cover ratio is currently 2.4 days.April 1, 2024 | marketbeat.comEnlivex Therapeutics (ENLV) Set to Announce Quarterly Earnings on TuesdayEnlivex Therapeutics (NASDAQ:ENLV) will be releasing earnings on Tuesday, April 2.March 22, 2024 | finanznachrichten.deEnlivex Therapeutics and Unusual Machines Interviews to Air on the RedChip Small Stocks, Big Money Show on Bloomberg TVMarch 16, 2024 | marketbeat.comShort Interest in Enlivex Therapeutics Ltd. (NASDAQ:ENLV) Expands By 51.2%Enlivex Therapeutics Ltd. (NASDAQ:ENLV - Get Free Report) was the target of a significant growth in short interest in the month of February. As of February 29th, there was short interest totalling 226,600 shares, a growth of 51.2% from the February 14th total of 149,900 shares. Based on an average trading volume of 104,700 shares, the days-to-cover ratio is presently 2.2 days.March 16, 2024 | finance.yahoo.comENLV Apr 2024 7.500 callMarch 9, 2024 | edition.cnn.comEnlivex Therapeutics Ltd.March 5, 2024 | marketbeat.comEnlivex Therapeutics (NASDAQ:ENLV) Trading Up 6.5%Enlivex Therapeutics (NASDAQ:ENLV) Trading Up 6.5%February 26, 2024 | finance.yahoo.comEnlivex Receives Regulatory Authorization From Israel’s Health Ministry For The Initiation Of Phase 1/2 Trial Evaluating Allocetra In Patients With Knee OsteoarthritisFebruary 22, 2024 | benzinga.comEnlivex Therapeutics Stock (NASDAQ:ENLV), Short Interest ReportFebruary 22, 2024 | finance.yahoo.comENLV May 2024 5.000 putFebruary 7, 2024 | finance.yahoo.comEnlivex Announces Issuance of New U.S. Patent Covering Allocetra Cells and Their Manufacturing MethodJanuary 17, 2024 | finance.yahoo.comEnlivex Receives IMOH Regulatory Authorization for the Initiation of a Multi-Country, Randomized, Controlled Phase I/II Trial Evaluating Allocetra in Up To 160 Patients with Moderate to Severe Knee OsteoarthritisDecember 20, 2023 | finance.yahoo.comEnlivex Announces Completion of Enrollment of Its Phase II Trial Evaluating Allocetra In Patients With SepsisDecember 16, 2023 | morningstar.comEnlivex Therapeutics Ltd ENLVDecember 12, 2023 | finance.yahoo.comIs Enlivex Therapeutics (NASDAQ:ENLV) In A Good Position To Deliver On Growth Plans?November 21, 2023 | finance.yahoo.comMediWound Announces Appointment of Shmulik Hess, Ph.D. as Chief Operating Officer and Chief Commercial OfficerSeptember 11, 2023 | finance.yahoo.comEnlivex Announces Reprioritization Plan and Second Quarter 2023 Financial ResultsSeptember 7, 2023 | finance.yahoo.comEnlivex to Present at the H.C. Wainwright 25th Annual Global Investment ConferenceAugust 2, 2023 | finance.yahoo.comEnlivex Announces Peer-Reviewed Publication in Frontiers in Immunology of Clinical Data Details Resolution of Acute Respiratory Distress Syndrome (ARDS) from two Phase I/II Trials Evaluating Allocetra in Patients with COVID-19July 31, 2023 | finance.yahoo.comEnlivex Announces Dosing of First Patient Under The Amended Protocol Of Its Phase II trial Evaluating Allocetra™ In Patients With SepsisJune 26, 2023 | finance.yahoo.comEnlivex Announces First Quarter 2023 Financial Results and Provides a Business UpdateJune 16, 2023 | benzinga.comThis Biotech Is Bringing Balance To The Body – How Homeostasis Is Critical To Fighting Everything From Sepsis To CancerJune 6, 2023 | finance.yahoo.comEnlivex to Present at the 2023 Jefferies Healthcare ConferenceMay 31, 2023 | finance.yahoo.comEnlivex Selected for an Elevator Pitch Presentation and two additional Poster Presentations at the 2023 Annual Meeting of the International Society for Cell & Gene TherapyMay 8, 2023 | finance.yahoo.comEnlivex Announces Issuance of European Patent Covering the Use of Allocetra™ to Prevent Cytokine Release Syndrome (CRS) Resulting from CAR T-Cell TherapyApril 20, 2023 | marketwatch.comEnlivex Receives Notice of Allowance for U.S. Patent Application Covering the Use of Allocetra(TM) in Patients Receiving CAR T-Cell Therapy Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address The death of Nvidia? (Ad)Today, I’m warning of another looming catastrophe. Only this time, it’s not in pot stocks, cryptos, or U.S. housing… it's in artificial intelligence. And unless you know what’s really going on in this sector, you could be wiped out. You see, while there is no doubt that the recent advancements in artificial intelligence are game-changing and will drive colossal innovation in every sector of the economy... There's also no escaping that The Big AI Die-Up is coming. So go here now to read my new report The Big AI Die-Up… while you still can. ENLV Media Mentions By Week ENLV Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. ENLV News Sentiment▼0.000.55▲Average Medical News Sentiment ENLV News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. ENLV Articles This Week▼30▲ENLV Articles Average Week Get Enlivex Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for ENLV and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies: ORGS News Today INCR News Today TLSA News Today CTXR News Today CRDF News Today ANL News Today IVVD News Today LFVN News Today VRCA News Today DERM News Today Headlines Tools: Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:ENLV) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Enlivex Therapeutics Ltd. Please log in to your account or sign up in order to add this asset to your watchlist. Share Enlivex Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.